On December 8, 2005, the FDA issued a public safety alert after the results of Paxil studies suggested that the drug increases the risk if heart defects, when women take it during the first three months of pregnancy.
Research published in the February 9, 2006 New England Journal of Medicine found that mothers who took SSRIs, in the second half of their pregnancies were 6 times more likely to give birth to infants with a lung disorder called persistent pulmonary hypertension (PPHN).
The condition occurs when a newborn's circulation system does not adapt to breathing outside the womb and causes high pressure in the blood vessels of the lungs making them unable to get enough oxygen into their bloodstream and can be fatal. Researchers estimate that between 10% and 20% of infants with PPHN will end up dying even after receiving treatment.
Critics say the news about dangerous drugs such as Paxil never reaches consumers because Big Pharma doles out billions of dollars to the media each year and if a negative study is about to come out, a company can just buy a few million bucks worth of ads from each major media outlet to ensure that the story gets minimal coverage, with the unspoken understanding that the ads will be canceled if the story gets too much exposure.
Families seeking justice for infants born with Paxil related birth defects can contact the Baum Hedlund Law Firm at: (800) 827-0087; http://www.baumhedlundlaw.com/
Evelyn Pringle
evelyn.pringle@sbcglobal.net
Written as part of the Paxil Litigation Monthly Round-Up, Sponsored by Baum Hedlund's Pharmaceutical Antidepressant Litigation Department, www.a-paxil-lawyer-source.com/, www.antidepressantadversereactions.com/, www.paxilbirthdefect.com
Research published in the February 9, 2006 New England Journal of Medicine found that mothers who took SSRIs, in the second half of their pregnancies were 6 times more likely to give birth to infants with a lung disorder called persistent pulmonary hypertension (PPHN).
The condition occurs when a newborn's circulation system does not adapt to breathing outside the womb and causes high pressure in the blood vessels of the lungs making them unable to get enough oxygen into their bloodstream and can be fatal. Researchers estimate that between 10% and 20% of infants with PPHN will end up dying even after receiving treatment.
Critics say the news about dangerous drugs such as Paxil never reaches consumers because Big Pharma doles out billions of dollars to the media each year and if a negative study is about to come out, a company can just buy a few million bucks worth of ads from each major media outlet to ensure that the story gets minimal coverage, with the unspoken understanding that the ads will be canceled if the story gets too much exposure.
Evelyn Pringle
evelyn.pringle@sbcglobal.net
Written as part of the Paxil Litigation Monthly Round-Up, Sponsored by Baum Hedlund's Pharmaceutical Antidepressant Litigation Department, www.a-paxil-lawyer-source.com/, www.antidepressantadversereactions.com/, www.paxilbirthdefect.com
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
1
1
1
